TNF-related apoptosis inducing ligand (TRAIL), is a cytokine which activates rapid apoptosis in transformed normal and tumor cells by binding to two death-signaling receptors, DR4 (TRAIL-R1) and DR5 (TRAIL-R2). TRAIL is expressed as a type-II TNF family transmembrane protein, but its extracellular domain can be released as a soluble cytokine upon proteolytic cleavage and commonly exists as a homotrimer. TRAIL is produced in a wide spectrum of tissues, including spleen, thymus, prostate, lung, kidney, and intestine. TRAIL has emerged as a promising candidate for cancer therapy on the basis of its unique ability to trigger apoptosis in various types of cancer cells without significant toxicity toward normal cells. The mechanism by which TRAIL induces apoptosis involves the formation of DISC (death inducing signaling complex) and activation of caspase-8, NFkappaB, and Bid, key regulators of increased inflammation and the apoptotic pathway.


TRAIL Singleplex Products

Our TRAIL immunoassays provide fast, accurate, reproducible, and highly sensitive measurements of TRAIL. MSD’s MULTI-ARRAY technology uses simple protocols, requires minimal sample, and quantifies analyte concentration over a wide dynamic range.


View All
TRAIL Multiplex Products

Our multiplex panels let you process up to 10 analytes simultaneously in each well of a MULTI-SPOT microplate. They provide the same outstanding performance as our singleplex immmunoassays while saving money, sample, and time.


View All
Browse Our Products

By Analytes
By Applications
Customer Service/Orders

Scientific/Technical Support

Instrument Support

Company Headquarters